Physician attitudes and prevalence of molecular testing in lung cancer

Background EGFR mutations and EML4-ALK rearrangements are key therapeutic targets in nonsquamous non-small-cell lung carcinoma (nsNSCLC). Current guidelines recommend testing all patients with advanced nsNSCLC (stages IIIB and IV). Objective To evaluate physician attitudes about molecular testing for nsNSCLC and to determine the rate of testing, the effect of biopsy sample size, and prevalence of driver mutations .